FIG 3.

VEGF and Ang2 levels in patient plasma and their effect on EC permeability. (A) VEGF levels in 7 SARS-CoV-2 plasma (001–005, 007, 008) and in normal pooled plasma were determined by the Quantikine Human VEGF Immunoassay. Optical density (OD) values were measured at 450 nm. TER was measured in confluent HLMVEC after the baseline was set. Cells were treated either with normal pooled plasma, withSARS-CoV-2 001 plasma, or with 20, 50, or 100 ng/mL of VEGF. Changes in TER were monitored for 18 h. (B) Ang2 levels in 7 SARS-CoV-2 plasma (001–005, 007, 008) and in normal pooled plasma were analyzed by the Quantikine Human Ang2 Immunoassay. OD values were measured at 450 nm. TER was measured on HLMVEC after baseline was set. Cells were treated either with normal pooled plasma, with SARS-CoV-2 001 plasma, or with 1, 20, 50, or 100 ng/mL of Ang2. The dashed line on the left panels of the figure shows the level of the VEGF or Ang2 levels in the normal plasma samples. Changes in TER were monitored for 18 h.